Plain-English translation of NCT06700070 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer medication called by injecting tiny doses directly into your tumor using a specialized device called CIVO. The goal is to see whether this treatment can activate your immune system to fight cancer cells within the tumor itself. Because the medication is delivered in very small amounts directly to the cancer, researchers can study how it works before testing it in larger groups of patients.
Doctors want to find new ways to boost the body's own immune system to fight cancer. This trial exists to test whether this medication can trigger immune cells to kill tumor cells when injected directly into the cancer, which is a faster and earlier way to test whether the treatment might work.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication directly into your tumor 1–2 days before your already-planned surgery using the CIVO injection device. The procedure involves tiny needle injections that deliver very small amounts of the medication into different areas of the tumor, and fluorescent markers help doctors track where each injection was placed. When you have your surgery a day or two later, the injected tumor tissue is removed and examined under a microscope to see how the medication affected the cancer cells.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States